Trial Profile
Safety tolerability and pharmacokinetics of cipargamin (KAE609) in healthy adult volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Oct 2015
Price :
$35
*
At a glance
- Drugs Cipargamin (Primary)
- Indications Malaria
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Novartis
- 09 Oct 2015 New trial record